TORONTO, March 2, 2015 /PRNewswire/ - Merus Labs
International Inc. (NASDAQ:MSLI; TSX:MSL) ("Merus" or "the
Company") announces that it has reached a settlement with
Apotex Inc. related to the previously disclosed Canadian
patent litigation on Enablex® (darifenacin hydrobromide). The
terms of the settlement are confidential, and the impact is not
financially material to the Company.
Enablex® is a prescription medicine used in adults to treat
overactive bladder syndrome. Marketing to Urologists and
other medical practitioners across Canada is expected to continue into the
foreseeable future.
About Merus Labs International Inc.
Merus Labs is a specialty pharmaceutical company focused on
acquiring established products. The Company leverages its expertise
in European and North American markets to optimize the value of
underdeveloped pharmaceutical assets.
Cautionary Statement
Certain statements contained in this press release may
constitute "forward-looking statements" within the meaning of
Section 21E (i) (1) of the United States Securities Exchange Act of
1934. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause Merus' actual
results to be materially different from any future results
expressed or implied by these statements. Such factors include the
following: general economic and business conditions, changes in
demand for Merus' products, changes in competition, the ability of
Merus to complete future acquisitions and to integrate these
acquisitions into its business, Merus' ability to complete future
debt and/or equity financings required to complete future
acquisitions, interest rate fluctuations, currency exchange rate
fluctuations, dependence upon and availability of qualified
personnel and changes in government regulation. In light of these
and other uncertainties, the forward-looking statements included in
this press release should not be regarded as a representation by
Merus that Merus' plans and objectives will be achieved.
These forward-looking statements speak only as of the date of
this press release, and we undertake no obligation to update or
revise the statements.
SOURCE Merus Labs International Inc.